WO2009158309A3 - Biphényle sulfonamides en tant que doubles antagonistes du récepteur d'angiotensine et d'endothéline - Google Patents

Biphényle sulfonamides en tant que doubles antagonistes du récepteur d'angiotensine et d'endothéline Download PDF

Info

Publication number
WO2009158309A3
WO2009158309A3 PCT/US2009/048136 US2009048136W WO2009158309A3 WO 2009158309 A3 WO2009158309 A3 WO 2009158309A3 US 2009048136 W US2009048136 W US 2009048136W WO 2009158309 A3 WO2009158309 A3 WO 2009158309A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
endothelin receptor
dual angiotensin
biphenyl sulfonamides
angiotensin endothelin
Prior art date
Application number
PCT/US2009/048136
Other languages
English (en)
Other versions
WO2009158309A2 (fr
Inventor
Andrew G. Cole
Patrick A. Jokiel
Marc-Raleigh Brescia
Lanying Qin
Ian Henderson
Original Assignee
Ligand Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc. filed Critical Ligand Pharmaceuticals Inc.
Publication of WO2009158309A2 publication Critical patent/WO2009158309A2/fr
Publication of WO2009158309A3 publication Critical patent/WO2009158309A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés biphényle sulfonamides qui sont des antagonistes combinés du récepteur d'angiotensine et d'endothéline et qui sont utiles dans le traitement d'états tels que l'hypertension ou d'autres maladies.
PCT/US2009/048136 2008-06-25 2009-06-22 Biphényle sulfonamides en tant que doubles antagonistes du récepteur d'angiotensine et d'endothéline WO2009158309A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7556208P 2008-06-25 2008-06-25
US61/075,562 2008-06-25

Publications (2)

Publication Number Publication Date
WO2009158309A2 WO2009158309A2 (fr) 2009-12-30
WO2009158309A3 true WO2009158309A3 (fr) 2010-04-22

Family

ID=41445249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048136 WO2009158309A2 (fr) 2008-06-25 2009-06-22 Biphényle sulfonamides en tant que doubles antagonistes du récepteur d'angiotensine et d'endothéline

Country Status (1)

Country Link
WO (1) WO2009158309A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112876424B (zh) * 2019-11-29 2023-06-30 上海拓界生物医药科技有限公司 血管紧张素ii受体及内皮素受体双重拮抗剂
WO2022266370A1 (fr) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan pour le traitement de la fibrose pulmonaire idiopathique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217973A (en) * 1991-07-05 1993-06-08 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists processes for preparing them and pharmaceutical compositions containing them
US5438063A (en) * 1993-06-07 1995-08-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines as angiotensin II antagonists
WO1995022543A1 (fr) * 1994-02-18 1995-08-24 Laboratori Guidotti S.P.A. Derives heterocycliques diazotes possedant une activite dirigee contre l'angiotensine ii
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
US6071913A (en) * 1997-03-28 2000-06-06 Development Center For Biotechnology Angiotensin II receptor antagonistic 1,2,4-triazin-5-one derivatives
WO2001044239A2 (fr) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217973A (en) * 1991-07-05 1993-06-08 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists processes for preparing them and pharmaceutical compositions containing them
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
US5438063A (en) * 1993-06-07 1995-08-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines as angiotensin II antagonists
WO1995022543A1 (fr) * 1994-02-18 1995-08-24 Laboratori Guidotti S.P.A. Derives heterocycliques diazotes possedant une activite dirigee contre l'angiotensine ii
US6071913A (en) * 1997-03-28 2000-06-06 Development Center For Biotechnology Angiotensin II receptor antagonistic 1,2,4-triazin-5-one derivatives
WO2001044239A2 (fr) * 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELLINGBOE, J.W. ET AL.: "Metabolites of the angiotensin II antagonist tasosartan: The importance of a second acidic group", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pages 4251 - 4260 *
KOWALA, M.C. ET AL.: "Novel dual action AT, and ETA receptor antagonists reduce blood pressure in experimental hypertension", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS., vol. 309, 2004, pages 275 - 284 *
LE BOURDONNEC, B. ET AL.: "Synthesis and pharmacological evaluation of new pyrazolidine-3,5-diones as AT angiotensin II receptor antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, 2000, pages 2685 - 2697 *
PATANI, G.A. ET AL.: "Bioisosterism: A rational approach in drug design", CHEMICAL REVIEWS, vol. 96, 1996, pages 3147 - 3176 *
SALIMBENI, A. ET AL.: "N-3-substituted pyrimidinones as potent, orally active, AT selective angiotensin II receptor antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, 1995, pages 4806 - 4820 *

Also Published As

Publication number Publication date
WO2009158309A2 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
WO2007109456A3 (fr) Biphényle isoxazole sulfonamides substituées en tant que double antagonistes des récepteurs angiotensine et endothéline
CY1123017T1 (el) Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης και της επαγομενης απο iga νεφροπαθειας
WO2008121767A3 (fr) Polypeptides cousus
WO2007119214A3 (fr) Traitement précoce de fibrose pulmonaire idiopathique
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
BRPI0922224A2 (pt) composições de inibidores de proteína tirosina quiinase receptora.
WO2011072099A3 (fr) Compositions et procédés comprenant des variants de protéase
WO2011047087A3 (fr) Détection de protéine par l'intermédiaire de nanorapporteurs
WO2010036631A3 (fr) Composés modulant sélectivement le récepteur cb2
WO2009037061A3 (fr) Utilisation de polypeptides de type hydrophobine comme renforçateurs de pénétration
WO2007114926A3 (fr) Antagonistes de la kinase
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d'opioïdes
WO2011130222A3 (fr) Compositions et procédés comprenant des protéases variantes
DE602007012072D1 (de) Orantagonisten
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
WO2008097561A8 (fr) Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation
WO2008014199A3 (fr) Composés modulant le récepteur cb2
WO2009067674A3 (fr) Polymorphes de base de sunitinib et procédés pour les préparer
WO2008042571A3 (fr) Composés chimiques
WO2010147792A3 (fr) Composés qui modulent sélectivement le récepteur cb2
WO2008089022A3 (fr) Cd200 et son récepteur, cd200r, module la masse osseuse par l'intermédiaire de la différenciation d'ostéoclastes
WO2009089234A3 (fr) Dibenzhydrylpipérazines substituées
WO2010055082A3 (fr) Nouvelle forme cristalline de malate de sunitinib

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770843

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27/04/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09770843

Country of ref document: EP

Kind code of ref document: A2